InMed Pharmaceuticals EBIT

The latest EBIT for INM is $-9.6B as of March 2026. That compares with $-14B in the prior-year period — up 29.4% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside InMed Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, INM's EBIT moved from $-14B to $-9.6B — a 29.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in InMed Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, INM currently prints $-9.6B for EBIT, while the sector average sits near $23B. That is roughly 141.7% below the sector mean. Large gaps often invite a closer look at InMed Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-9.6B for INM is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting INM's EBIT ($-9.6B), review year-over-year change from $-14B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.